{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:38Z","timestamp":1787009078610,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG065154"],"award-info":[{"award-number":["R01AG065154"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR081040"],"award-info":[{"award-number":["R01AR081040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG063707"],"award-info":[{"award-number":["R01AG063707"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR076349"],"award-info":[{"award-number":["R01AR076349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial was performed at the Mayo Clinic which randomized postmenopausal women to placebo, propranolol (40 or 80\u00a0mg twice daily), atenolol (50\u00a0mg\/d), or nebivolol (5\u00a0mg\/d) to determine changes in bone turnover markers (BTMs) and in BMD over 20\u00a0wk. Pharmacogenetic effects and microRNA-mediated mechanisms involving beta adrenergic receptor and related genes have previously been found. We sought to validate these effects and discover new candidates in an ancillary study to the pilot clinical trial. We genotyped all participants and performed microRNA (miRNA) sequencing at baseline and at 20\u00a0wk for 24 participants from the atenolol or placebo groups. We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs. Our miRNA results showed a significant treatment effect for miR-19a-3p over time with atenolol use in the low-responder group compared to placebo. Overall, the longitudinal miRNA analysis showed a large number of miRNAs which were up-regulated over the trial in the low responders but not the high responders compared to placebo, of which miR-19a-3p was one example. Finally, we compared the response to atenolol treatment for cardiovascular traits (pulse and blood pressure) with the response for the bone resorption marker, C-terminal telopeptide, and found a largely independent effect. Our results have implications for personalized therapy and for understanding mechanisms of BB treatment effect on bone.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae200","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T07:29:32Z","timestamp":1734074972000},"page":"231-240","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacogenetic and microRNA mechanisms of beta blocker use on bone"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5399-9602","authenticated-orcid":false,"given":"Christine W","family":"Lary","sequence":"first","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]},{"name":"MaineHealth Institute for Research , Center for Molecular Medicine, Scarborough, ME 04074 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-3775","authenticated-orcid":false,"given":"Elizabeth J","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zannatun","family":"Nayema","sequence":"additional","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler A","family":"Roy","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research , Center for Molecular Medicine, Scarborough, ME 04074 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Peters","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research , Center for Molecular Medicine, Scarborough, ME 04074 ,","place":["United States"]},{"name":"University of Maine , Graduate School of Biomedical Science and Engineering, Orono, ME 04469 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin T","family":"Scott","sequence":"additional","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Roux Institute at Northeastern University , Department of Public Health and Health Sciences, Portland, ME 04101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Brown","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research , Center for Molecular Medicine, Scarborough, ME 04074 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J","family":"Motyl","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research , Center for Molecular Medicine, Scarborough, ME 04074 ,","place":["United States"]},{"name":"University of Maine , Graduate School of Biomedical Science and Engineering, Orono, ME 04469 ,","place":["United States"]},{"name":"Tufts University School of Medicine , Department of Medicine, Boston, MA 02111 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-0114","authenticated-orcid":false,"given":"David G","family":"Monroe","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Kogod Center on Aging, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Khosla","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Kogod Center on Aging, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"11","key":"2025020314510441200_ref1","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1172\/JCI122151","article-title":"Sympathetic beta1-adrenergic signaling contributes to regulation of human bone metabolism","volume":"128","author":"Khosla","year":"2018","journal-title":"J Clin Invest"},{"issue":"9","key":"2025020314510441200_ref2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00198-007-0354-8","article-title":"Beta-blocker use and risk of fractures in men and women from the general population: the MONICA\/KORA Augsburg cohort study","volume":"18","author":"Meisinger","year":"2007","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025020314510441200_ref3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1359\/JBMR.0301214","article-title":"Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study","volume":"19","author":"Pasco","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025020314510441200_ref4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.bone.2012.08.126","article-title":"Beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients","volume":"51","author":"Song","year":"2012","journal-title":"Bone"},{"issue":"1","key":"2025020314510441200_ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00198-013-2498-z","article-title":"Beta-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects","volume":"25","author":"Toulis","year":"2014","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025020314510441200_ref6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bone.2010.10.170","article-title":"Association between beta-blocker use and fracture risk: the Dubbo osteoporosis epidemiology study","volume":"48","author":"Yang","year":"2011","journal-title":"Bone"},{"issue":"9","key":"2025020314510441200_ref7","doi-asserted-by":"publisher","first-page":"e10388","DOI":"10.1002\/jbm4.10388","article-title":"Association of beta blocker use with bone mineral density in the Framingham osteoporosis study: a cross-sectional study","volume":"4","author":"Lary","year":"2020","journal-title":"JBMR Plus"},{"issue":"3","key":"2025020314510441200_ref8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0092-8674(02)01049-8","article-title":"Leptin regulates bone formation via the sympathetic nervous system","volume":"111","author":"Takeda","year":"2002","journal-title":"Cell"},{"issue":"7032","key":"2025020314510441200_ref9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature03398","article-title":"Leptin regulation of bone resorption by the sympathetic nervous system and CART","volume":"434","author":"Elefteriou","year":"2005","journal-title":"Nature"},{"issue":"5","key":"2025020314510441200_ref10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jbmr.4523","article-title":"Propranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL\/6J mice","volume":"37","author":"Treyball","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025020314510441200_ref11","first-page":"94","article-title":"Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis","volume":"8","author":"Bonnet","year":"2008","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"6","key":"2025020314510441200_ref12","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jbmr.1594","article-title":"Deletion of B-adrenergic receptor 1, 2, of both leads to different bone phenotypes and response to mechanical stimulation","volume":"27","author":"Pierroz","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025020314510441200_ref13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1084\/jem.20102608","article-title":"Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual","volume":"208","author":"Kajimura","year":"2011","journal-title":"J Exp Med"},{"issue":"11","key":"2025020314510441200_ref14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/jama.292.11.1326","article-title":"Use of beta-blockers and risk of fractures","volume":"292","author":"Schlienger","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"2025020314510441200_ref15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2025020314510441200_ref16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/pgs-2018-0191","article-title":"The future of pharmacogenetics in the treatment of hypertension","volume":"20","author":"Cunningham","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"3","key":"2025020314510441200_ref17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.115.06345","article-title":"Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans","volume":"67","author":"Gong","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"2025020314510441200_ref18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006463","article-title":"Genome-wide association approach identified novel genetic predictors of heart rate response to beta-blockers","volume":"7","author":"Shahin","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2025020314510441200_ref19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/clpt.2008.139","article-title":"Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension","volume":"84","author":"Pacanowski","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"2025020314510441200_ref20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1056\/NEJMoa010819","article-title":"The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization","volume":"345","author":"Dishy","year":"2001","journal-title":"N Engl J Med"},{"issue":"15","key":"2025020314510441200_ref21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1161\/01.CIR.0000065231.07729.92","article-title":"Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly","volume":"107","author":"Heckbert","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"2025020314510441200_ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2025020314510441200_ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab092","article-title":"Pharmacogenomic effects of \u03b2-blocker use on femoral neck bone mineral density","volume":"5","author":"Nevola","year":"2021","journal-title":"Journal of the Endocrine Society"},{"issue":"7","key":"2025020314510441200_ref24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.euroneuro.2012.06.013","article-title":"Blood microRNA changes in depressed patients during antidepressant treatment","volume":"23","author":"Bocchio-Chiavetto","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"2025020314510441200_ref25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12688\/f1000research.1-50.v1","article-title":"The distribution of circulating microRNA and their relation to coronary disease","volume":"1","author":"Freedman","year":"2012","journal-title":"F1000Res"},{"issue":"4","key":"2025020314510441200_ref26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/acel.12622","article-title":"Cross-sectional relations of whole-blood miRNA expression levels and hand grip strength in a community sample","volume":"16","author":"Murabito","year":"2017","journal-title":"Aging Cell"},{"issue":"7","key":"2025020314510441200_ref27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/1354750X.2014.935957","article-title":"Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients","volume":"19","author":"Li","year":"2014","journal-title":"Biomarkers"},{"issue":"5","key":"2025020314510441200_ref28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00223-015-0036-z","article-title":"Serum circulating MicroRNAs as biomarkers of osteoporotic fracture","volume":"97","author":"Panach","year":"2015","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2025020314510441200_ref29","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/jbmr.2175","article-title":"Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures","volume":"29","author":"Seeliger","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025020314510441200_ref30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejps.2019.02.013","article-title":"Effect of plasma microRNA on antihypertensive response to beta blockers in the pharmacogenomic evaluation of antihypertensive responses (PEAR) studies","volume":"131","author":"Solayman","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2025020314510441200_ref31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/CIRCRESAHA.115.303252","article-title":"MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade","volume":"115","author":"Castaldi","year":"2014","journal-title":"Circ Res"},{"issue":"8","key":"2025020314510441200_ref32","doi-asserted-by":"publisher","first-page":"BR309","DOI":"10.12659\/msm.883263","article-title":"Beta-adrenoceptor regulates miRNA expression in rat heart","volume":"18","author":"Hou","year":"2012","journal-title":"Med Sci Monit"},{"issue":"1","key":"2025020314510441200_ref33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jbmr.4160","article-title":"miRNA mechanisms underlying the association of beta blocker use and bone mineral density","volume":"36","author":"Nevola","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025020314510441200_ref34","first-page":"642","article-title":"MiR-19a overexpression contributes to heart failure through targeting ADRB1","volume":"8","author":"Miao","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"2025020314510441200_ref35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbm4.10115","article-title":"MicroRNA and human bone health","volume":"3","author":"Cheng","year":"2019","journal-title":"JBMR Plus"},{"issue":"11","key":"2025020314510441200_ref36","doi-asserted-by":"publisher","first-page":"e13617","DOI":"10.15252\/emmm.202013617","article-title":"Antagonizing microRNA-19a\/b augments PTH anabolic action and restores bone mass in osteoporosis in mice","volume":"14","author":"Taipaleenmaki","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2025020314510441200_ref37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbrc.2019.06.083","article-title":"MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs","volume":"516","author":"Chen","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2025020314510441200_ref38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1083\/jcb.201403138","article-title":"HDAC4 integrates PTH and sympathetic signaling in osteoblasts","volume":"205","author":"Obri","year":"2014","journal-title":"J Cell Biol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae200\/61157126\/zjae200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/2\/231\/61157126\/zjae200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/2\/231\/61157126\/zjae200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:51:13Z","timestamp":1738576273000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/2\/231\/7923459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,13]]},"published-print":{"date-parts":[[2025,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae200","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,13]]}}}